Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: A phase II study from Indiana University

Annals of Oncology

Volumn 17, Issue 1, 2006, Pages 97-103

  Kurup, A ^a   Lin, C W ^c   Murry, D J ^c   Dobrolecki, L ^b   Estes, D ^a   Yiannoutsos, C T ^a   Mariano, L ^a   Sidor, C ^d   Hickey, R ^b   Hanna, N ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d ENTREMED INC   (United States)

Author keywords

Angiogenesis; Carboplatin; Lung cancer; Paclitaxel; RhAngiostatin

Indexed keywords

ANGIOSTATIN; CARBOPLATIN; PACLITAXEL; RECOMBINANT HUMAN ANGIOSTATIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DYSPNEA; FATIGUE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INFECTION; LUNG ADENOCARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE; VOMITING;

AGED; ANGIOSTATINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROTEOMICS; RECOMBINANT PROTEINS; SURVIVAL RATE; TIME FACTORS;

EID: 29844452745     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj055     Document Type: Article

References (35)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311: 899-909.
2. Marine P, Pampallona S, Preatoni F et al. Chemotherapy vs supportive care in advanced non-small cell lung cancer: Results of a meta-analysis of the literature. Chest 1994; 106: 861-865.
3. Stephens R, Fairlamb N, Gower N et al. The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 2002; 21: 291a.
4. Kelly K, Crowley J, Bunn P et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
5. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
6. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-739.
7. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
8. Grunstein J, Roberts WG, Mathieu-Costello O et al. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999; 59: 1592-1598.
9. Brekken RA, Overholser JP, Stastny VA et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/FIk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000; 60: 5117-5124.
10. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
11. Viloria-Petit A, Miquerol L, Yu JL et al. Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J 2003; 22: 4091-4102.
12. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990; 3: 267-282.
13. Ferrar N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5: 1359.
14. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
15. Yang JC, Haworth L, Sherry RM et al. A randomized trial of Bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427.
16. Bergers G, Song S, Meyer-Morse N, Bergsland E. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287.
17. Morgan B, Thomas AL, Drevs J et al. Dyanmic contrast enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 2063; 21: 3955.
18. Holash J, Davis S, Papadopoulos N et al. VEGF-Trap: A VEGF blocker with potent anti-tumor effects. Proc Natl Acad Sci USA 2002; 99: 11393.
19. Kuo CJ, Farnebo F, Yu EY et al. Comparative evaluation of antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001; 98: 4605.
20. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
21. O'Reilly MS. The preclinical evaluation of angiogenesis inhibitors. Invest New Drugs 1997; 15: 5.
22. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277.
23. MacDonald NJ, Murad AC, Fogler WE et al. The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3. Biochem Biophys Res Commun 1999; 264: 469-477.
24. DeMoraes ED, Fogler WE, Grant D. Recombinant human angiostatin (rhA): A Phase I clinical trial assessing safety, pharmacokinetics (PK) and pharmacodynamics (PD). Proc Am Soc Clin Oncol 2001; 20: 3a.
25. Sim BK, O'Reilly MS, Liang H et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997; 57: 1329-1334.
26. Drixler TA, Rinkes IH, Ritchie ED et al. Continous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res 2000; 60: 1761-1765.
27. Velde EA, Vogten JM, Gebbink MF et al. Enhanced antitumor efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br J Surg 2002; 89: 1302-1309.
28. Maucer HJ, Hanna NN, Beckett MA et al. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 1998; 394: 287-291.
29. Beerepoot LV, Witteveen EO, Groenewegen G et al. Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: A pharmacokinetic and long-term safety study. Clin Cancer Res 2003; 9: 4025-4033.
30. Miller AB, Hogestraeten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
31. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456-1463.
32. Sandler AB, Gray R, Brahmer J et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. ASCO Meetings 1 June 2005; 4.
33. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
34. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
35. Issaq HJ, Veenstra TD, Conrads TP et al. The SELDI-TOF MS approach to proteomics: Protein profiling and biomarker identification. Biochem Biophys Res Commun 2002; 292: 587-592.